Vectus Biosystems Limited (VBS) fair value: what the stock is really worth
As of Oct 9, 2026: fair value of Vectus Biosystems Limited A$0.30, price A$0.11, upside +185.7%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.
How to read this chart
60‑month range A$0.0370 – A$2.00 · fair‑value band A$0.1600 – A$1.02 · the A$0.1050 price screens below the A$0.3000 fair value. Dashed = 300-day average. As of Oct 4, 2026.
Follow Vectus Biosystems in your weekly email
Every Wednesday you see whether Vectus Biosystems is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis.
Show more
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue to fibrosis, and scarring. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. The company was incorporated in 2005 and is based in Rosebery, Australia.
Stock analysis
Vectus Biosystems Limited (VBS) currently trades at A$0.1050, while our model-based Fair Value estimate is A$0.3000, implying the stock looks roughly 65.0% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of A$1.16 per share, and 8 of the 10 models we run sit above the A$0.1050 price.
Bear case: the Multiples group reads lowest at A$0.1700, and 2 of the 10 models stay below the price. Evidence for this calculation is low.
Scenario range: A$0.1600 (bear) to A$1.02 (bull), the price of A$0.1050 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Vectus Biosystems Limited reported revenue of A$478K in FY2025 versus A$180 in FY2021, a compound +617.9%/yr. Reported net income was A$1.6M in FY2026.
Key figures
Market cap A$6.8M (≈ $4.8M) · P/E ratio 3.5 · P/S ratio 2.47 · EPS (TTM) A$0.0300 · Net margin 56.3% · Return on equity 139% · Return on assets (EBIT) −116% · Operating margin 76.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 76% below its 52-week high and 42% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 186%, VBS screens cheaper than that median.
Fair Value models
Bear A$0.1600Fair Value A$0.3000Bull A$1.02
Price A$0.1050 · Upside +185.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (A$0.0300 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−58.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−28.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+56.3%
Start year 2020 (pandemic)
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.6%
’13
’14
’16
’17
’18
’20
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−5,303.3% (2020) → −352.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
Compare Vectus Biosystems Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 591 stocks
Beats the industry median on 10/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score48 · Above median
Fair Value upside+185.7% · Top 25%
Profitability
Return on equity (TTM)139.3% · Top 25%
Return on assets37.4% · Top 25%
Net margin (TTM)56.3% · Top 25%
Operating margin (TTM)76.4% · Top 25%
Growth and dividend
Revenue growth31.7% · Top 25%
Balance sheet
Debt / equity0.09× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Vectus Biosystems Limited (VBS) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of A$0.3000 versus a price of A$0.1050, about +186% upside (undervalued).
What is the fair value of VBS?
Our model-based fair value for Vectus Biosystems Limited is A$0.3000 (as of Oct 4, 2026), built from audited fundamentals. The current price: A$0.1050.
What is the quality score of VBS?
Vectus Biosystems Limited has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vectus Biosystems Limited (VBS)?
Our model-based price target is the fair value of A$0.3000 (as of Oct 4, 2026) from 10 valuation models. Cautious scenario A$0.1600, optimistic scenario A$1.02. It is a calculation from audited fundamentals, not an analyst target.
What is the Vectus Biosystems Limited stock forecast for 2026?
Our models put fair value at A$0.3000, about +186% upside versus a price of A$0.1050 (undervalued). Cautious scenario A$0.1600, optimistic scenario A$1.02. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Vectus Biosystems Limited (VBS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vectus Biosystems Limited it is A$0.3000 per share (as of Oct 4, 2026), against a price of A$0.1050. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Vectus Biosystems Limited stock overvalued or undervalued in 2026?
As of Oct 4, 2026, VBS trades below its calculated fair value: price A$0.1050, fair value A$0.3000, a gap of about +186% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VBS?
No. The price is what the market pays today (A$0.1050); the fair value is what the company's own numbers justify (A$0.3000). For Vectus Biosystems Limited the two are A$0.1950 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vectus Biosystems Limited worth?
The market values Vectus Biosystems Limited at about A$6.8M (market capitalisation, as of Oct 4, 2026). Per share that is A$0.1050; our models calculate a fair value of A$0.3000 per share.
What do the bullish and bearish scenarios say about VBS?
Our models span a range for Vectus Biosystems Limited: cautious scenario A$0.1600, base A$0.3000, optimistic A$1.02 per share (as of Oct 4, 2026, price A$0.1050). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of VBS?
Vectus Biosystems Limited trades at a price-to-earnings ratio of 3.5 (as of Oct 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of A$0.3000 is built from several models across several years. Other multiples: P/B 2.1, P/S 1.7, EV/EBITDA 3.0.
How solid is the balance sheet of Vectus Biosystems Limited (VBS)?
Balance-sheet figures for Vectus Biosystems Limited (as of Oct 4, 2026): return on equity 139.3%, debt of 0.09 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is VBS from its 52-week high?
Vectus Biosystems Limited trades at A$0.1050, about 76% below its 52-week high of A$0.4400 and 42% above the low of A$0.0740 (as of Oct 9, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.3000 is for.
Which stocks are comparable to Vectus Biosystems Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vectus Biosystems Limited stock attractive at the current price?
The data as of Oct 4, 2026: price A$0.1050, calculated fair value A$0.3000 (+186%), Quality Score 48/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VBS calculated?
We run Vectus Biosystems Limited through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$0.3000, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Vectus Biosystems Limited currently trades 65 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vectus Biosystems Limited (VBS)?
The closing price on Oct 9, 2026 was A$0.1050. Our model-based fair value is A$0.3000, about +186% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vectus Biosystems Limited right now?
The price is below even our cautious bear case (A$0.1600). The market is more pessimistic than our downside scenario. The model range is unusually wide (A$0.1600 to A$1.02). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (48/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Vectus Biosystems Limited
How large is the market capitalisation of Vectus Biosystems Limited (VBS)?
The market capitalisation of Vectus Biosystems Limited is A$6.8M (≈ $4.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vectus Biosystems Limited (VBS)?
The price-to-sales ratio of Vectus Biosystems Limited is 2.47 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Vectus Biosystems Limited (VBS)?
Earnings per share at Vectus Biosystems Limited are A$0.0300 (price ÷ EPS = P/E 3.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Vectus Biosystems Limited (VBS)?
The net margin of Vectus Biosystems Limited is 56.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vectus Biosystems Limited (VBS)?
The return on equity (ROE) of Vectus Biosystems Limited is 139% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vectus Biosystems Limited (VBS)?
On an EBIT basis the return on assets of Vectus Biosystems Limited is −116% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vectus Biosystems Limited (VBS)?
The operating margin of Vectus Biosystems Limited is 76.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vectus Biosystems Limited (VBS)?
Revenue at Vectus Biosystems Limited is growing +31.7% versus a year earlier (3y avg −28.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Vectus Biosystems Limited (VBS) generate?
The free cash flow of Vectus Biosystems Limited is −A$573K (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Vectus Biosystems Limited (VBS) hold?
Vectus Biosystems Limited holds more cash than debt, A$172K net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Vectus Biosystems Limited in the live analysis
One click puts Vectus Biosystems Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
